To the Editor:Light chain deposition disease(LCDD)is a rare systemic complication of plasma cell disorders that primarily affects the kidneys,and LCDD can lead to chronic kidney failure.[1]Before the development of no...To the Editor:Light chain deposition disease(LCDD)is a rare systemic complication of plasma cell disorders that primarily affects the kidneys,and LCDD can lead to chronic kidney failure.[1]Before the development of novel anti-plasmacyte agents,the overall prognosis of LCDD patients was poor.The introduction of novel plasmacyte-targeted therapies,such as the proteasome inhibitor bortezomib,has improved kidney survival in LCDD patients.[2]However,the kidney response rate of LCDD patients to bortezomib-based treatment remains approximately 50%,and 25.7%of patients progress to end-stage kidney disease(ESKD)within 60 months.Daratumumab,an anti-CD38 monoclonal antibody that has been available in China since 2021,has shown promising results in both multi ple myeloma(MM)and light-chain(AL)amyloidosis patients.[3,4]Several case series have demonstrated rapid hematological responses and preservation of kidney function in LCDD patients treated with daratumumab who were previously treated with bortezomib.[5,6]However,the efficacy of a combination of daratumumab and bortezomib compared to regimes involving bortezomib alone in newly diagnosed LCDD patients has yet to be systematically assessed.We retrospectively reviewed our database to address this issue and conducted a comparative study.展开更多
基金supported by grants from the National High Level Hospital Clinical Research Funding(Scientific Research Seed Fund of Peking University First Hospital)(No.2022SF37)National High Level Hospital Clinical Research Funding(No.2022CR07)+1 种基金National Natural Science Foundation of China(No.82070747)CAMS Innovation Fund for Medical Sciences(No.2019-I2M-5-046).
文摘To the Editor:Light chain deposition disease(LCDD)is a rare systemic complication of plasma cell disorders that primarily affects the kidneys,and LCDD can lead to chronic kidney failure.[1]Before the development of novel anti-plasmacyte agents,the overall prognosis of LCDD patients was poor.The introduction of novel plasmacyte-targeted therapies,such as the proteasome inhibitor bortezomib,has improved kidney survival in LCDD patients.[2]However,the kidney response rate of LCDD patients to bortezomib-based treatment remains approximately 50%,and 25.7%of patients progress to end-stage kidney disease(ESKD)within 60 months.Daratumumab,an anti-CD38 monoclonal antibody that has been available in China since 2021,has shown promising results in both multi ple myeloma(MM)and light-chain(AL)amyloidosis patients.[3,4]Several case series have demonstrated rapid hematological responses and preservation of kidney function in LCDD patients treated with daratumumab who were previously treated with bortezomib.[5,6]However,the efficacy of a combination of daratumumab and bortezomib compared to regimes involving bortezomib alone in newly diagnosed LCDD patients has yet to be systematically assessed.We retrospectively reviewed our database to address this issue and conducted a comparative study.
